Search

Your search keyword '"Kenler, Andrew"' showing total 12 results
Start Over Author "Kenler, Andrew"
12 results on '"Kenler, Andrew"'

1. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence

Author

Fine, Richard E., Gilmore, Richard C., Tomkovich, Kenneth R., Dietz, Jill R., Berry, Michael P., Hernandez, Lydia E., Columbus, Karen S., Seedman, Susan A., Fisher, Carla S., Han, Linda K., Manahan, Eric R., Hicks, Randy D., Vaidya, Rashmi P., Curcio, Lisa D., Sevrukov, Alexander B., Kenler, Andrew S., Taback, Bret, Chen, Margaret, Miller, Megan E., Gold, Linsey, Anglin, Beth V., Aoun, Hussein D., Simmons, Rache M., Feldman, Sheldon M., and Boolbol, Susan K.

Published
2024
Full Text
View/download PDF

2. ASO Visual Abstract: Cryoablation without Excision for Early Stage Breast Cancer; ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence

Author

Fine, Richard E., Gilmore, Richard C., Tomkovich, Kenneth R., Dietz, Jill R., Berry, Michael P., Hernandez, Lydia E., Columbus, Karen S., Seedman, Susan A., Fisher, Carla S., Han, Linda K., Manahan, Eric R., Hicks, Randy D., Vaidya, Rashmi P., Curcio, Lisa D., Sevrukov, Alexander B., Kenler, Andrew S., Taback, Bret, Chen, Margaret, Miller, Megan E., Gold, Linsey, Anglin, Beth V., Aoun, Hussein D., Simmons, Rache M., Feldman, Sheldon M., and Boolbol, Susan K.

Published
2024
Full Text
View/download PDF

3. Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial

Author

Fine, Richard E., Gilmore, Richard C., Dietz, Jill R., Boolbol, Susan K., Berry, Michael P., Han, Linda K., Kenler, Andrew S., Sabel, Michael, Tomkovich, Kenneth R., VanderWalde, Noam A., Chen, Margaret, Columbus, Karen S., Curcio, Lisa D., Feldman, Sheldon M., Gold, Linsey, Hernandez, Lydia, Manahan, Eric R., Seedman, Susan A., Vaidya, Rashmi P., Sevrukov, Alexander B., Aoun, Hussein D., Hicks, Randy D., and Simmons, Rache M.

Published
2021
Full Text
View/download PDF

4. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072

Author

Simmons, Rache M, Ballman, Karla V, Cox, Charles, Carp, Ned, Sabol, Jennifer, Hwang, Rosa F, Attai, Deanna, Sabel, Michael, Nathanson, David, Kenler, Andrew, Gold, Linsey, Kaufman, Cary, Han, Linda, Bleznak, Aaron, Stanley Smith, J, Holmes, Dennis, Fornage, Bruno, Le-Petross, Carisa, Hoda, Syed, McCall, Linda, Hunt, Kelly K, and on behalf of the ACOSOG investigators

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Aging, Clinical Research, Breast Cancer, Cancer, Adult, Aged, Aged, 80 and over, Breast Neoplasms, Carcinoma, Ductal, Breast, Cryosurgery, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Treatment Outcome, ACOSOG investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundCryoablation is a well-established technique to treat fibroadenomas. Pilot studies suggest this could be an effective non-surgical treatment for breast cancer. American College of Surgeons Oncology Group Z1072 is a phase II trial exploring the effectiveness of cryoablation in the treatment of breast cancers.MethodsThe primary endpoint of Z1072 was the rate of complete tumor ablation, defined as no remaining invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) on pathologic examination of the targeted lesion. A secondary objective was to evaluate the negative predictive value of magnetic resonance imaging (MRI) to determine residual IBC or DCIS. Eligible patients included those with unifocal invasive ductal breast cancer ≤2 cm, with

Published
2016

5. ASO Visual Abstract: Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer—3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial

Author

Fine, Richard E., Gilmore, Richard C., Dietz, Jill R., Boolbol, Susan K., Berry, Michael P., Han, Linda K., Kenler, Andrew S., Sabel, Michael, Tomkovich, Kenneth R., VanderWalde, Noam A., Chen, Margaret, Columbus, Karen S., Curcio, Lisa D., Feldman, Sheldon M., Gold, Linsey, Hernandez, Lydia, Manahan, Eric R., Seedman, Susan A., Vaidya, Rashmi P., Sevrukov, Alexander B., Aoun, Hussein D., Hicks, Randy D., and Simmons, Rache M.

Published
2021
Full Text
View/download PDF

9. Early Enteral Feeding in Postsurgical Cancer Patients

Author

Kenler, Andrew S., primary, Swails, Wendy S., additional, Driscoll, David F., additional, DeMichele, Stephen J., additional, Daley, Brian, additional, Babineau, Timothy J., additional, Peterson, Myron B., additional, and Bistrian, Bruce R., additional

Published
1996
Full Text
View/download PDF

12. A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients

Author

Babineau, Timothy J., Hackford, Alan, Kenler, Andrew, Bistrian, Bruce, Forse, R. Armour, Fairchild, Patrick G., Heard, Stephen, Keroack, Mark, Caushaj, Philip, and Benotti, Peter

Abstract

OBJECTIVE: To examine the safety and efficacy of multiple doses of PGG-glucan (poly- [ 1-6]-B-Dglucopyranosyl-[ 1-3]-B-D-glucopyranose) in high-risk patients undergoing major thoracic or abdominal surgery. DESIGN: An interventional, multicenter, double-blind, randomized, placebo-controlled study. SETTING: Four university-affiliated medical centers. PATIENTS: Sixty-seven high-risk patients undergoing major thoracic or abdominal surgery. INTERVENTION: Patients were randomized in a 1:1:1:1 ratio to receive saline placebo or PGG-glucan at a dose of 0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg or 2.0 mg/kg. One dose was administered before surgery and three doses were administered after surgery. MAIN OUTCOME MEASURES: To examine the safety and efficacy of PGG-glucan infusion and to identify potentially important factors for a planned phase III study. RESULTS: A dose-response trend with regard to infection incidence among patients who received PGG-glucan was observed. Serious infections occurred in four patients who received placebo and in three patients who received PGG-glucan at a dose of 0.1 mg/kg. However, only one patient who received PGG-glucan at a high dose had a serious infection. The incidence and severity of adverse events was comparable in all groups. CONCLUSIONS: PGG-glucan was generally safe and well tolerated, may decrease postoperative infection rates, and warrants further investigation in a planned phase III trial.(Arch Surg. 1994;129:1204-1210)

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results